Allen Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Allen Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-16,051	Closed	-$582K	–	227
2016 Q4	$582K	Sell	16,051 -4,022	-20%	-$161K	0.03%	130
2016 Q3	$924K	Sell	20,073 -1,031	-5%	-$53.8K	0.06%	98
2016 Q2	$1.06M	Sell	21,104 -43,816	-67%	-$2.33M	0.07%	80
2016 Q1	$3.47M	Buy	+64,920	New	+$3.81M	0.27%	47
2015 Q1	–	Sell	-4,325	Closed	-$249K	–	243
2014 Q4	$249K	Sell	4,325 -1,838	-30%	-$102K	0.02%	208
2014 Q3	$331K	Buy	+6,163	New	+$327K	0.03%	154

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Allen Investment Management's TEVA Position: Q1 2017 in Review

Allen Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 16,051 shares — an estimated $582K sold.

Allen Investment Management first reported a position in TEVA in Q3 2014 and held it in 6 quarters. The position peaked at $3.47M in Q1 2016. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Allen Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Allen Investment Management sold 16,051 Teva Pharmaceuticals shares in Q1 2017, an estimated $582K.
Allen Investment Management first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Allen Investment Management's Teva Pharmaceuticals position peaked at $3.47M in Q1 2016.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Allen Investment Management's 13F filing for Q1 2017, filed 15 May 2017.